People on Ozempic and other GLP-1 agonist drugs commonly report they no longer have constant, incessant thoughts about food.

The global anorexiant market is set for significant expansion, with a projected compound annual growth rate (CAGR) of 5.1% over the forecast period, according to a recent study by Future Market ...

Retatrutide mimics the effects of naturally occurring gut hormones to improve metabolic health. Stimulating insulin release ...

Glenmark launches Empagliflozin and combinations in India under Glempa brand, aiming to improve glycemic control and reduce ...

Very few people are currently being prescribed drugs for weight loss on the NHS in Scotland, research by BBC Scotland News ...

People using weight-loss injections are being warned of potential side effects that could impact their ability to drive ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

Nanexa AB announces today that the first patient has been dosed in the 30 mg dose group in the ongoing Phase I study with NEX-22, the company's one-month formulation of liraglutide. The ongoing Phase ...

Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year ...

Hikma launched liraglutide, a generic version of an earlier Novo Nordisk weight loss drug, in the US in December. Liraglutide, which Novo sells as Victoza for diabetes and Saxenda for weight loss, has ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...